AZD-5312 is a small molecule androgen receptor inhibitor in early clinical development by AstraZeneca. It has completed a Phase I study in androgen receptor tumors and was part of a terminated Phase I trial in combination with enzalutamide for metastatic castration-resistant prostate cancer.